NEOGEN CORP — Form 8-K
Filed July 30, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
Neogen reported FY 2026 revenue of $870.4M (−2.7% YoY), with core growth of 1.9%. Food Safety segment showed 3.1% Q4 growth (5.8% core, highest since FY23); Animal Safety declined 8.2% (0.5% core) but improved 7% sequentially. Adjusted EBITDA was $177.8M (20.4% margin). Company is divesting its global Genomics business to Zoetis for $160M gross proceeds (~$140M net after taxes/costs), expected to close by end of H1 FY27; Australian and NZ regulators moved into phase-2 review. FY 2027 guidance: $880–885M revenue, $180–182M Adjusted EBITDA (includes $92M Genomics revenue pre-divestiture). Petrifilm manufacturing transition to Lansing on track for November 2026 start.
Why this rating
Revenue decline and margin compression offset by Genomics divestiture ($160M, ~6% of market cap), operational improvements, and positive Food Safety momentum. Moderate near-term impact.
See more from July 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.